Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer relies on Alacer addition; Latin America strong for Bayer OTCs; Allegra Japan launch drives Sanofi OTC growth; Herbalife overcomes investor “noise”; Rx slide offsets Merck OTC gains.
You may also be interested in...
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.